PD-L1 tagged posts

Novel Regulator of Immune Evasion in Cancer identified

Novel regulator of immune evasion in cancer identified
Representative images from immunohistochemical staining of PD-L1, ATXN3, IRF1, and HIF-2α in human lung adenocarcinoma (LUAD) and melanoma patients. Courtesy of Deyu Fang, PhD. Credit: Journal of Clinical Investigation (2023). DOI: 10.1172/JCI167728

Northwestern Medicine investigators have identified a previously unknown regulator of tumor immune evasion, which may help improve the efficacy of current and future antitumor immunotherapies, according to recent findings published in the Journal of Clinical Investigation.

“The study provides a molecular insight into understanding why some cancer patients cannot be treated by the checkpoint blockade antitumor therapy, but others can,” said Deyu Fang, Ph.D...

Read More

Antidepressants Inhibit Cancer Growth in Mice

SSRIs and other serotonin blockers cause immune cells to recognize tumor cells again and eliminate them efficiently. (Bild: istock.com/Design Cells)

Classic antidepressants could help improve modern cancer treatments. They slowed the growth of pancreatic and colon cancers in mice, and when combined with immunotherapy, they even stopped the cancer growth long-term. In some cases the tumors disappeared completely, researchers at UZH and USZ have found. Their findings will now be tested in human clinical trials.

Serotonin is a neurotransmitter that is also known as the happiness hormone because of its beneficial effects on mood. In depressed people, the concentration of serotonin in the brain is reduced. The hormone also influences many other functions throughout the body...

Read More